Axim Biotechnologies Inc (OTCMKTS:AXIM) Reports Upcoming Clinical Milestones

In the imminent 12-18 months, Axim Biotechnologies Inc (OTCMKTS:AXIM) intends to accomplish a number of clinical programs. The company intends to conclude the open-label Phase 2 clinical study with CanChew+® 50 mg Cannabidiol in subjects with IBS at the University of Wageningen.

It will complete Phase I-III clinical study with MedChew® Rx in four different academic centers for treatment of spasticity and chronic pain in people with multiple sclerosis. Also, there is a plan to complete bioequivalence trial of its proprietary chewing gum based functional delivery mechanism to Marinol to assist cure patients with chemotherapy led vomiting and nausea and AIDS patients fighting weight and appetite loss.

The highlights

Axim Biotechnologies intends to complete proof of concept trial with MedChew RL™ in people with restless leg syndrome. It will begin pre and clinical studies for treatment of IBD. The company will also seek to commence clinical trials in dry eye syndrome and glaucoma with AX 1606 and AX-1603.

Another study on list is to begin clinical studies at the University of British Columbia in Canada on subjects complaining of illicit drug-related psychosis. The company also intends to launch proof of concept trial for treatment of subjects with post-haerpetic neuralgia. It will advance enhanced topical system for cure of psoriasis, and vitiligo and atopic dermatitis with an improved delivery platform.

During Q3 2017, Axim reported that the USPTO issued to company a patent that claims ophthalmic offerings constituting cannabinoids for the indicative relief of conjunctival inflammation and treatment of glaucoma. Another Notice of Allowance was also given, for the process to utilize the same cannabinoid solutions for the cure of glaucoma as well as symptomatic relief of conjunctival inflammation.

Axim’s has 22 allowed or registered trademarks nationally, with corresponding global trademarks pending or registered, and another five trademark applications, pending based on products developed and formulated by company.